Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Double Good News For AstraZeneca’s Breast Cancer Drugs

By Vandana Singh
April 29, 9:25 AM
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

AZN

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

GE HealthCare Receives FDA Clearance For Portrait VSM, Building In Its Growing Ecosystem Of Connected Patient Monitoring Solutions

By Benzinga Newsdesk
April 29, 9:13 AM
The portable vital signs monitor (VSM) adds to GE HealthCare's growing Portrait Ecosystem to help clinicians make timely treatment decisions and detect patient deterioration earlier with a streamlined spot check

GEHC

Read More
2 minute read
  • Biotech
  • General
  • News

Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine To Further Evaluate Synergy Between Antibody Drug Conjugates And (Z)-Endoxifen

By Benzinga Newsdesk
April 29, 8:34 AM
Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and

ATOS

Read More
2 minute read
  • Biotech
  • General
  • News

Pasithea Therapeutics Announces PAS-004 Abstract Accepted For Poster Presentation At 2024 ASCO Annual Meeting

By Benzinga Newsdesk
April 29, 8:14 AM
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type

KTTA

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

NKGen Biotech Announces FDA Clearance Of IND Application For SNK01 NK Cell Therapy in Parkinson’s Disease

By Benzinga Newsdesk
April 29, 8:08 AM
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson's disease. The Company expects to initiate a Phase 1 clinical trial in

NKGN

Read More
2 minute read
  • Biotech
  • General
  • Legal
  • News

“LGBTQ Health Care Bias Protections Gets HHS Green Light; Health Programs Can’t Discriminate Against LGBTQ Patients” – Bloomberg Law

By Benzinga Newsdesk
April 26, 4:47 PM
https://news.bloomberglaw.com/daily-labor-report/lgbtq-health-care-bias-protections-gets-hhs-greenlightHealth programs can't discriminate against LGBTQ patientsRule follows US Supreme Court decision in BostockThe Biden

SPY

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News
  • Top Stories

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle

By Vandana Singh
April 26, 2:45 PM
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent infringement in mRNA technology.

BNTX

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

FDA Green Lights Pfizer’s Gene Therapy For Rare Bleeding Disorder Hemophilia

By Vandana Singh
April 26, 2:30 PM
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.

CSLLY

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

Ex-Humira Growth Platform Drives AbbVie’s Q1 Performance, Drugmaker Lifts Annual Profit Outlook

By Vandana Singh
April 26, 9:54 AM
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.

ABBV

Read More
1 minute read
  • Biotech
  • General
  • Global
  • News

Amgen Seeks EMA Approval For Teprotumumab In Moderate To Severe Thyroid Eye Disease

By Benzinga Newsdesk
April 26, 9:02 AM
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted

AMGN

Posts pagination

Previous 1 … 50 51 52 … 733 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service